{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:51:46Z","timestamp":1760151106457,"version":"build-2065373602"},"reference-count":91,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01CA247497","U01CA239258"],"award-info":[{"award-number":["R01CA247497","U01CA239258"]}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","award":["Career Development Award"],"award-info":[{"award-number":["Career Development Award"]}],"id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Treatment for Hodgkin lymphoma (HL) has evolved considerably from the time it was originally described in the 19th century with many patients now being cured with frontline therapy. Despite these advances, upwards of 10% of patients experience progressive disease after initial therapy with an even higher percentage relapsing. Until recently there had been limited therapeutic options for relapsed and\/or refractory HL outside of highly intensive chemotherapy with stem cell rescue. Improved understanding of the pathophysiology of HL, coupled with the emergence of more targeted therapeutics, has reshaped how we view the treatment of relapsed\/refractory HL and its prognosis. With this, there has been an increased focus on immunotherapies that can reprogram the immune system to better overcome the immunosuppressive milieu found in HL for improved cancer cell killing. In particular, chimeric antigen receptor (CAR) T cells are emerging as a valuable therapeutic tool in this area. Building on the success of antibody-drug conjugates directed against CD30, CAR T cells engineered to recognize the same antigen are now reaching patients. Though still in its infancy, CAR T therapy for relapsed\/refractory HL has shown exceptional promise in early-stage clinical trials with the potential for durable responses even in patients who had progressed through multiple lines of prior therapy. Here we will review currently available data on the use of CAR T cells in HL, strategies to optimize their effectiveness, and how this therapy may fit into the treatment paradigm of HL going forward.<\/jats:p>","DOI":"10.3390\/jpm12020197","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:59:21Z","timestamp":1643709561000},"page":"197","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Emerging Role of CAR T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6321-5971","authenticated-orcid":false,"given":"Jeremy A.","family":"Meier","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Medicine, Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"},{"name":"Department of Medicine, Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI200316624","article-title":"Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling","volume":"111","author":"Klein","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"Intergruppo Italiano Linfomi ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Voorhees, T.J., and Beaven, A.W. (2020). Therapeutic updates for relapsed and refractory classical hodgkin lymphoma. Cancers (Basel), 12.","DOI":"10.3390\/cancers12102887"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: The era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11899-017-0398-6","article-title":"Targeting immune system alterations in hodgkin lymphoma","volume":"12","author":"Grover","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/acg2.54","article-title":"CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm","volume":"2","author":"Hill","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Grover, N.S., and Savoldo, B. (2019). Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5415-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/asheducation-2008.1.326","article-title":"Management of Hodgkin lymphoma in relapse after autologous stem cell transplant","volume":"2018","author":"Crump","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-021-00840-5","article-title":"Novel therapies in the treatment of hodgkin lymphoma","volume":"22","author":"Ansell","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2020.11.009","article-title":"Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma","volume":"21","author":"Adam","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00002371-200407000-00008","article-title":"The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease","volume":"27","author":"Bollard","year":"2004","journal-title":"J. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing cd30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: An open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ho, C., Ruella, M., Levine, B.L., and Svoboda, J. (2021). Adoptive T-cell Therapy for Hodgkin Lymphoma. Blood Adv.","DOI":"10.1182\/bloodadvances.2021005304"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Voorhees, T.J., Zhao, B., Oldan, J., Hucks, G.E., Khandani, A., Dittus, C., Smith, J., Morrison, J.K., Cheng, C., and Ivanova, A. (2021). Pretherapy metabolic tumor volume associates with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv.","DOI":"10.1182\/bloodadvances.2021005385"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","article-title":"Tumor-associated macrophages in classical Hodgkin lymphoma: Hormetic relationship to outcome","volume":"10","author":"Werner","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e20200851","DOI":"10.1084\/jem.20200851","article-title":"B cells and cancer: To B or not to B?","volume":"218","author":"Fridman","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13198","article-title":"Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy","volume":"168","author":"Romano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1182\/blood-2019-122752","article-title":"MDSC suppression of CAR T cells can be reduced by targeted signaling disruption","volume":"134","author":"Cervantes","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2021.39.15_suppl.1032","article-title":"Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy","volume":"39","author":"Nalawade","year":"2021","journal-title":"JCO"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1268","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Caballero","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells","volume":"106","author":"Guercio","year":"2021","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00262-010-0920-3","article-title":"Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia","volume":"60","author":"Gassner","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"He, C., Zhou, Y., Li, Z., Farooq, M.A., Ajmal, I., Zhang, H., Zhang, L., Tao, L., Yao, J., and Du, B. (2020). Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion. Cancers (Basel), 12.","DOI":"10.3390\/cancers12071969"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Rooney","year":"2009","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory Hodgkin lymphoma and CD30+ cutaneous T cell lymphoma","volume":"138","author":"Grover","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2016.30","article-title":"CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse","volume":"17","author":"Diepstra","year":"2016","journal-title":"Genes Immun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI129208","article-title":"State of the art in CAR T cell therapy for CD19+ B cell malignancies","volume":"130","author":"Frigault","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2019-122846","article-title":"Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma","volume":"134","author":"Voorhees","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2021005343","article-title":"Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel\/ref Hodgkin Lymphoma","volume":"6","author":"Dave","year":"2021","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2017-09-772681","article-title":"Management of relapsed\/refractory classical Hodgkin lymphoma in transplant-ineligible patients","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: Analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/annonc\/mdg206","article-title":"Autologous stem cell transplantation for primary refractory Hodgkin\u2019s disease: Results and clinical variables affecting outcome","volume":"14","author":"Constans","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/bmt.2017.99","article-title":"Long-term follow-up of allogeneic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"52","author":"Giaccone","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin\u2019s disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2013A prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: A systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: Comparisons of safety and long-term efficacy of allogeneic Hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1021.e1","DOI":"10.1016\/j.jtct.2021.08.022","article-title":"Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia","volume":"12","author":"Tschernia","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41409-021-01396-6","article-title":"Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: A deceptive friend story","volume":"56","author":"Farttoosi","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Riches, M.L., Shea, T.C., Ivanova, A., Cheng, C., Laing, S., Seegars, M.B., Dotti, G., Savoldo, B., Grover, N.S., and Serody, J.S. (2021;, January 8\u201312). Infusion of CD30 CAR T Cells Is Safe and Effective As Consolidation Following Autologous Hematopoietic Stem Cell Transplant. Proceedings of the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Salt Lake City, UT, USA.","DOI":"10.1016\/S2666-6367(21)00093-2"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.bbmt.2020.04.003","article-title":"Exploring the dilemma of allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy: To transplant or not?","volume":"26","author":"Bouziana","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: An intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:18Z","timestamp":1760134338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jpm12020197"],"URL":"https:\/\/doi.org\/10.3390\/jpm12020197","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}